% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:19204,
      author       = {Galldiks, N. and Langen, K.-J.},
      title        = {{A}nwendung der {A}minosäure-{PET} in der {D}iagnostik und
                      {T}herapie von zerebralen {G}liomen ({U}se of amino acid
                      {PET} in the diagnostic and treatment management of cerebral
                      gliomas)},
      journal      = {Fortschritte der Neurologie, Psychiatrie},
      volume       = {80},
      issn         = {0720-4299},
      address      = {Stuttgart [u.a.]},
      publisher    = {Thieme},
      reportid     = {PreJuSER-19204},
      pages        = {17 - 23},
      year         = {2012},
      note         = {Record converted from VDB: 12.11.2012},
      abstract     = {Structural as well as functional imaging methods are of
                      special importance in neurooncology. Improvements of
                      radionuclide and magnetic resonance-based imaging modalities
                      over the past decade have enabled clinicians to
                      non-invasively assess the dynamics of disease-specific
                      processes at the molecular level in patients with malignant
                      gliomas. To date, a range of complementary imaging
                      parameters have been established in the diagnostic work-up
                      of patients with brain tumours. Magnetic resonance imaging
                      (MRI) provides morphological information as well as
                      functional information such as vascular permeability, cell
                      density, tumour perfusion, and metabolic information by
                      using magnetic resonance spectroscopy. The use of
                      radiolabelled amino acids for positron emission tomography
                      (PET) allows a better delineation of tumour margins and
                      improves targeting of biopsy and radiotherapy, and planning
                      surgery. In addition, amino acid imaging appears useful in
                      distinguishing tumour recurrence from non-specific
                      post-therapeutic scar tissue, in predicting prognosis in
                      low-grade gliomas, and in monitoring metabolic response
                      during treatment. Taken together, MRI and PET provide
                      complementary information about tumour biology and activity,
                      thereby resulting in an improved understanding of the
                      kinetics of tumour growth and therefore allow new insights
                      into the pathophysiology of malignant brain tumours.
                      However, multimodal imaging studies comparing the value of
                      amino acid PET and functional methods of MRI (e. g.,
                      perfusion and diffusion weighted imaging) are needed. From
                      these studies, surrogate MRI and PET imaging techniques need
                      to be derived to gain complementary structural and
                      functional information of brain tumours that can be placed
                      into common clinical practice which will optimise the
                      clinical management of patients with malignant gliomas.},
      keywords     = {Amino Acids: diagnostic use / Biopsy / Brain: pathology /
                      Brain: radionuclide imaging / Brain Neoplasms: pathology /
                      Brain Neoplasms: radionuclide imaging / Brain Neoplasms:
                      therapy / Combined Modality Therapy / Glioma: pathology /
                      Glioma: radionuclide imaging / Glioma: therapy / Humans /
                      Magnetic Resonance Imaging / Neoplasm Recurrence, Local /
                      Neurosurgical Procedures / Patient Care Planning /
                      Positron-Emission Tomography: methods / Prognosis /
                      Radiopharmaceuticals: diagnostic use / Amino Acids (NLM
                      Chemicals) / Radiopharmaceuticals (NLM Chemicals) / J
                      (WoSType)},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {Funktion und Dysfunktion des Nervensystems (FUEK409) /
                      89572 - (Dys-)function and Plasticity (POF2-89572)},
      pid          = {G:(DE-Juel1)FUEK409 / G:(DE-HGF)POF2-89572},
      shelfmark    = {Clinical Neurology / Psychiatry},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:22161228},
      UT           = {WOS:000299650200015},
      doi          = {10.1055/s-0031-1281851},
      url          = {https://juser.fz-juelich.de/record/19204},
}